Cargando…

Outcome of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia before Second-Generation FLT3 Tyrosine Kinase Inhibitors: A Toulouse–Bordeaux DATAML Registry Study

A recent phase 3 trial showed that the outcome of patients with relapsed/refractory (R/R) FLT3-mutated acute myeloid leukemia (AML) improved with gilteritinib, a single-agent second-generation FLT3 tyrosine kinase inhibitor (TKI), compared with standard of care. In this trial, the response rate with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bertoli, Sarah, Dumas, Pierre-Yves, Bérard, Emilie, Largeaud, Laetitia, Bidet, Audrey, Delabesse, Eric, Tavitian, Suzanne, Gadaud, Noémie, Leguay, Thibaut, Leroy, Harmony, Rieu, Jean-Baptiste, Vial, Jean-Philippe, Vergez, François, Lechevalier, Nicolas, Luquet, Isabelle, Klein, Emilie, Sarry, Audrey, De Grande, Anne-Charlotte, Récher, Christian, Pigneux, Arnaud
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226007/ https://www.ncbi.nlm.nih.gov/pubmed/32218221 http://dx.doi.org/10.3390/cancers12040773

Ejemplares similares

Real-World Outcomes of Patients with Refractory or Relapsed FLT3-ITD Acute Myeloid Leukemia: A Toulouse-Bordeaux DATAML Registry Study
por: Dumas, Pierre-Yves, et al.
Publicado: (2020)

Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes
por: Galtier, Jean, et al.
Publicado: (2021)

Vitamin C and D supplementation in acute myeloid leukemia
por: Mouchel, Pierre Luc, et al.
Publicado: (2023)

Phenotypically-defined stages of leukemia arrest predict main driver mutations subgroups, and outcome in acute myeloid leukemia
por: Vergez, François, et al.
Publicado: (2022)

CD34(+)CD38(−)CD123(+) Leukemic Stem Cell Frequency Predicts Outcome in Older Acute Myeloid Leukemia Patients Treated by Intensive Chemotherapy but Not Hypomethylating Agents
por: Vergez, François, et al.
Publicado: (2020)

Genomic landscape of hyperleukocytic acute myeloid leukemia
por: Largeaud, Laetitia, et al.
Publicado: (2022)

A case of cup‐like blasts associated with B‐lymphoblastic leukemia without NPM1 and FLT3 internal tandem duplication mutations
por: Rieu, Jean‐Baptiste, et al.
Publicado: (2020)

Outcome of patients aged 60‐75 years with newly diagnosed secondary acute myeloid leukemia: A single‐institution experience
por: Bertoli, Sarah, et al.
Publicado: (2019)

Unsupervised Flow Cytometry Analysis Allows for an Accurate Identification of Minimal Residual Disease Assessment in Acute Myeloid Leukemia
por: Vial, Jean Philippe, et al.
Publicado: (2021)

A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries
por: Bérard, Emilie, et al.
Publicado: (2022)

Improved outcome for AML patients over the years 2000–2014
por: Bertoli, Sarah, et al.
Publicado: (2017)

CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia
por: Bertoli, Sarah, et al.
Publicado: (2015)

Dexamethasone in hyperleukocytic acute myeloid leukemia
por: Bertoli, Sarah, et al.
Publicado: (2018)

Azacitidine or intensive chemotherapy for older patients with secondary or therapy-related acute myeloid leukemia
por: Dumas, Pierre-Yves, et al.
Publicado: (2017)

Acute myeloid leukemia with myelodysplasia-related changes and basophilic differentiation
por: Rieu, Jean-Baptiste, et al.
Publicado: (2020)

Do not jump to hasty conclusions: all gamma delta T-cells neoplasms are not aggressive!
por: Vergez, François, et al.
Publicado: (2019)

Autophagy Targeting and Hematological Mobilization in FLT3-ITD Acute Myeloid Leukemia Decrease Repopulating Capacity and Relapse by Inducing Apoptosis of Committed Leukemic Cells
por: Dupont, Marine, et al.
Publicado: (2022)

CPX-351 in FLT3-mutated acute myeloid leukemia
por: Andrews, Claire, et al.
Publicado: (2023)

Therapy-related acute myeloid leukemia following treatment of lymphoid malignancies
por: Bertoli, Sarah, et al.
Publicado: (2016)

Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine
por: Bories, Pierre, et al.
Publicado: (2020)

When dystrophic plasma cells do not recognize themselves in the mirror
por: Rieu, Jean‐Baptiste, et al.
Publicado: (2020)

Further Activation of FLT3 Mutants by FLT3 Ligand
por: Zheng, Rui, et al.
Publicado: (2011)

Inhibition of the proteasome and proteaphagy enhances apoptosis in FLT3‐ITD‐driven acute myeloid leukemia
por: Lopez‐Reyes, Rosa G., et al.
Publicado: (2020)

The implication of FLT3 amplification for FLT targeted therapeutics in solid tumors
por: Lim, Sung Hee, et al.
Publicado: (2016)

Hematopoietic niche drives FLT3-ITD acute myeloid leukemia resistance to quizartinib via STAT5-and hypoxia-dependent upregulation of AXL
por: Dumas, Pierre-Yves, et al.
Publicado: (2019)

Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3
por: Nagai, Kozo, et al.
Publicado: (2018)

OTS167 blocks FLT3 translation and synergizes with FLT3 inhibitors in FLT3 mutant acute myeloid leukemia
por: Eisfelder, Bartholomew J., et al.
Publicado: (2021)

Somatic genetic alterations predict hematological progression in GATA2 deficiency
por: Largeaud, Laetitia, et al.
Publicado: (2023)

Overcoming Resistance to FLT3 Inhibitors in the Treatment of FLT3-Mutated AML
por: Lam, Stephen S.Y., et al.
Publicado: (2020)

Unusual Transmission of Plasmodium falciparum, Bordeaux, France, 2009
por: Vareil, Marc-Olivier, et al.
Publicado: (2011)

Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells
por: Chen, Fangli, et al.
Publicado: (2016)

Bristol and Bordeaux
por: Cosh, J. A.
Publicado: (1957)

The Bordeaux Conference
Publicado: (1924)

The Flt3L/Flt3 Axis in Dendritic Cell Biology and Cancer Immunotherapy
por: Cueto, Francisco J., et al.
Publicado: (2021)

Mutated Flt3Lg Provides Reduced Flt3 Recycling Compared to Wild-Type Flt3Lg and Retains the Specificity of Flt3Lg-Based CAR T-Cell Targeting in AML Models
por: Maiorova, Varvara, et al.
Publicado: (2023)

Flt3 Ligand Regulates Dendritic Cell Development from Flt3(+) Lymphoid and Myeloid-committed Progenitors to Flt3(+) Dendritic Cells In Vivo
por: Karsunky, Holger, et al.
Publicado: (2003)

Natural Flt3Lg-Based Chimeric Antigen Receptor (Flt3-CAR) T Cells Successfully Target Flt3 on AML Cell Lines
por: Maiorova, Varvara, et al.
Publicado: (2021)

Inhibition of FLT3 Expression by Green Tea Catechins in FLT3 Mutated-AML Cells
por: Ly, Bui Thi Kim, et al.
Publicado: (2013)

DOCK2 Interacts with FLT3 and Modulates the Survival of FLT3-Expressing Leukemia Cells
por: Wu, Min, et al.
Publicado: (2016)

Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML
por: Wang, Aoli, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_lh0f9tu7qc4jsa4etek03u42o6